Trial Outcomes & Findings for Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NCT NCT00561834)

Results Overview

The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

2 participants

Primary outcome timeframe

Baseline and 6 months

Results posted on

2016-09-30

Participant milestones
Measure	Ranibizumab ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment
Overall Study STARTED	2
Overall Study COMPLETED	2
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Baseline characteristics by cohort
Measure	Ranibizumab n=2 Participants ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment
Age, Continuous	63.5 years STANDARD_DEVIATION 4.95 • n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants

Timeframe: Baseline and 6 months

The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.

Outcome measures
Measure	Ranibizumab n=2 Participants ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment
Change in Visual Acuity lines change in visual acuity -subject 2	3 lines change in Snellen chart
Change in Visual Acuity lines change in visual acuity subject 1	4 lines change in Snellen chart

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Rocky Mountain Lions Eye Institute, Dept. of Ophthalmology

Phone: 720-848-2500